IDO activates regulatory T cells and blocks their conversion into Th17-like T cells

Babak Baban, Phillip R. Chandler, Madhav D. Sharma, Jeanene Pihkala, Pandelakis A. Koni, David H. Munn, Andrew L. Mellor

Research output: Contribution to journalArticle

273 Citations (Scopus)

Abstract

TLR ligands are effective vaccine adjuvants because they stimulate robust proinflammatory and immune effector responses and they abrogate suppression mediated by regulatory T cells (Tregs). Paradoxically, systemic administration of high doses of CpGs that bind to TLR9 ligands stimulated Tregs in mouse spleen to acquire potent suppressor activity dependent on interactions between programmed death-1 and its ligands. This response to CpG treatment manifested 8-12 h and was mediated by a rare population of plasmacytoid dendritic cells (CD19+ pDC) induced to express the immunosuppressive enzyme IDO after TLR9 ligation. When IDO was blocked, CpG treatment did not activate Tregs, but instead stimulated pDCs to uniformly express the proinflammatory cytokine IL-6, which in turn reprogrammed Foxp3-lineage Tregs to express IL-17. Thus, CpG-induced IDO activity in pDCs acted as a pivotal molecular switch that induced Tregs to acquire a stable suppressor phenotype, while simultaneously blocking CpG-induced IL-6 expression required to reprogram Tregs to become Th17-like effector T cells. These findings support the hypothesis that IDO dominantly controls the functional status of Tregs in response to inflammatory stimuli in physiological settings.

Original languageEnglish (US)
Pages (from-to)2475-2483
Number of pages9
JournalJournal of Immunology
Volume183
Issue number4
DOIs
StatePublished - Aug 15 2009

Fingerprint

Regulatory T-Lymphocytes
Ligands
T-Lymphocytes
Interleukin-6
Interleukin-17
Immunosuppressive Agents
Dendritic Cells
Ligation
Vaccines
Spleen
Cytokines
Phenotype
Enzymes
Population

ASJC Scopus subject areas

  • Immunology

Cite this

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. / Baban, Babak; Chandler, Phillip R.; Sharma, Madhav D.; Pihkala, Jeanene; Koni, Pandelakis A.; Munn, David H.; Mellor, Andrew L.

In: Journal of Immunology, Vol. 183, No. 4, 15.08.2009, p. 2475-2483.

Research output: Contribution to journalArticle

Baban, Babak ; Chandler, Phillip R. ; Sharma, Madhav D. ; Pihkala, Jeanene ; Koni, Pandelakis A. ; Munn, David H. ; Mellor, Andrew L. / IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. In: Journal of Immunology. 2009 ; Vol. 183, No. 4. pp. 2475-2483.
@article{3f621f076d2143a18ab26b26c7c5016b,
title = "IDO activates regulatory T cells and blocks their conversion into Th17-like T cells",
abstract = "TLR ligands are effective vaccine adjuvants because they stimulate robust proinflammatory and immune effector responses and they abrogate suppression mediated by regulatory T cells (Tregs). Paradoxically, systemic administration of high doses of CpGs that bind to TLR9 ligands stimulated Tregs in mouse spleen to acquire potent suppressor activity dependent on interactions between programmed death-1 and its ligands. This response to CpG treatment manifested 8-12 h and was mediated by a rare population of plasmacytoid dendritic cells (CD19+ pDC) induced to express the immunosuppressive enzyme IDO after TLR9 ligation. When IDO was blocked, CpG treatment did not activate Tregs, but instead stimulated pDCs to uniformly express the proinflammatory cytokine IL-6, which in turn reprogrammed Foxp3-lineage Tregs to express IL-17. Thus, CpG-induced IDO activity in pDCs acted as a pivotal molecular switch that induced Tregs to acquire a stable suppressor phenotype, while simultaneously blocking CpG-induced IL-6 expression required to reprogram Tregs to become Th17-like effector T cells. These findings support the hypothesis that IDO dominantly controls the functional status of Tregs in response to inflammatory stimuli in physiological settings.",
author = "Babak Baban and Chandler, {Phillip R.} and Sharma, {Madhav D.} and Jeanene Pihkala and Koni, {Pandelakis A.} and Munn, {David H.} and Mellor, {Andrew L.}",
year = "2009",
month = "8",
day = "15",
doi = "10.4049/jimmunol.0900986",
language = "English (US)",
volume = "183",
pages = "2475--2483",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - IDO activates regulatory T cells and blocks their conversion into Th17-like T cells

AU - Baban, Babak

AU - Chandler, Phillip R.

AU - Sharma, Madhav D.

AU - Pihkala, Jeanene

AU - Koni, Pandelakis A.

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2009/8/15

Y1 - 2009/8/15

N2 - TLR ligands are effective vaccine adjuvants because they stimulate robust proinflammatory and immune effector responses and they abrogate suppression mediated by regulatory T cells (Tregs). Paradoxically, systemic administration of high doses of CpGs that bind to TLR9 ligands stimulated Tregs in mouse spleen to acquire potent suppressor activity dependent on interactions between programmed death-1 and its ligands. This response to CpG treatment manifested 8-12 h and was mediated by a rare population of plasmacytoid dendritic cells (CD19+ pDC) induced to express the immunosuppressive enzyme IDO after TLR9 ligation. When IDO was blocked, CpG treatment did not activate Tregs, but instead stimulated pDCs to uniformly express the proinflammatory cytokine IL-6, which in turn reprogrammed Foxp3-lineage Tregs to express IL-17. Thus, CpG-induced IDO activity in pDCs acted as a pivotal molecular switch that induced Tregs to acquire a stable suppressor phenotype, while simultaneously blocking CpG-induced IL-6 expression required to reprogram Tregs to become Th17-like effector T cells. These findings support the hypothesis that IDO dominantly controls the functional status of Tregs in response to inflammatory stimuli in physiological settings.

AB - TLR ligands are effective vaccine adjuvants because they stimulate robust proinflammatory and immune effector responses and they abrogate suppression mediated by regulatory T cells (Tregs). Paradoxically, systemic administration of high doses of CpGs that bind to TLR9 ligands stimulated Tregs in mouse spleen to acquire potent suppressor activity dependent on interactions between programmed death-1 and its ligands. This response to CpG treatment manifested 8-12 h and was mediated by a rare population of plasmacytoid dendritic cells (CD19+ pDC) induced to express the immunosuppressive enzyme IDO after TLR9 ligation. When IDO was blocked, CpG treatment did not activate Tregs, but instead stimulated pDCs to uniformly express the proinflammatory cytokine IL-6, which in turn reprogrammed Foxp3-lineage Tregs to express IL-17. Thus, CpG-induced IDO activity in pDCs acted as a pivotal molecular switch that induced Tregs to acquire a stable suppressor phenotype, while simultaneously blocking CpG-induced IL-6 expression required to reprogram Tregs to become Th17-like effector T cells. These findings support the hypothesis that IDO dominantly controls the functional status of Tregs in response to inflammatory stimuli in physiological settings.

UR - http://www.scopus.com/inward/record.url?scp=70149101645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149101645&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0900986

DO - 10.4049/jimmunol.0900986

M3 - Article

VL - 183

SP - 2475

EP - 2483

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -